PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver1

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Immunology

• Publication date

  2007-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.178.5.2714PMID 17312113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis

  2006cited by this paper
• PD‐L1 and PD‐L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Interferon-γ acts directly on CD8+ T cells to increase their abundance during virus infection

  2005cited by this paper
• T Cells Undergo Rapid ON/OFF but Not ON/OFF/ON Cycling of Cytokine Production in Response to Antigen1

  2005cited by this paper
• Oscillating CD8(+) T cell effector functions after antigen recognition in the liver.

  2005cited by this paper
• In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

  2005cited by this paper
• PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ

  2004cited by this paper
• B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts

  2004cited by this paper
• PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.

  2004cited by this paper
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• Different immunogenicity of H‐2 Kb‐restricted epitopes in natural variants of the hepatitis B surface antigen

  2003cited by this paper
• PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

  2003cited by this paper
• CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection

  2003cited by this paper
• Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis.

  2003cited by this paper
• Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

  2003cited by this paper
• Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

  2003cited by this paper
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

  2003cited by this paper
• Expression of Programmed Death 1 Ligands by Murine T Cells and APC1

  2002cited by this paper
• B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis1

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Cytokine-Sensitive Replication of Hepatitis B Virus in Immortalized Mouse Hepatocyte Cultures

  2002cited by this paper
• Expression and Regulation of the PD‐L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells

  2002cited by this paper
• Immunogenicity and Tolerogenicity of Hepatitis B Virus Structural and Nonstructural Proteins: Implications for Immunotherapy of Persistent Viral Infections

  2002cited by this paper
• PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.

  2001cited by this paper
• Blocking Chemokine Responsive to γ–2/Interferon (IFN)-γ Inducible Protein and Monokine Induced by IFN-γ Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes

  2001cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice1

  2001cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• Polyclonality and multispecificity of the CTL response to a single viral epitope.

  1998cited by this paper
• Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.

  1998cited by this paper
• How do cytotoxic lymphocytes kill their targets?

  1998cited by this paper
• Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice.

  1997cited by this paper
• DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes.

  1997cited by this paper
• Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes

  1997cited by this paper
• Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

  1996cited by this paper
• Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.

  1996cited by this paper
• Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

  1996cited by this paper
• High-level hepatitis B virus replication in transgenic mice

  1995cited by this paper
• Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis

  1993cited by this paper
• Immune response against lymphocytic choriomeningitis virus infection in mice without CD8 expression

  1991cited by this paper

• Differential induction of PD-L1 expression in cells infected with feline infectious peritonitis virus and feline enteric coronavirus.

  2025cites this paper
• Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors

  2025cites this paper
• Antiviral therapy for hepatitis B virus infection is beneficial for the prognosis hepatocellular carcinoma

  2025cites this paper
• The role of PD-L1 gene silencing on growth, migration, and apoptosis in oral squamous carcinoma cell line HN-5

  2025cites this paper
• Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment

  2024cites this paper
• The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy

  2024cites this paper
• A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative

  2024cites this paper
• Immune checkpoint inhibitors in infectious disease

  2024cites this paper
• CX3CL1/Fractalkine: A Potential Biomarker for Liver Fibrosis in Chronic HBV Infection

  2024cites this paper
• HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis

  2023cites this paper
• Identification of antibodies cross-reactive with woodchuck immune cells and activation of virus-specific and global cytotoxic T cell responses by anti-PD-1 and anti-PD-L1 in experimental chronic hepatitis B and persistent occult hepadnaviral infection

  2022cites this paper
• PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B

  2022cites this paper
• Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms

  2022cites this paper
• Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

  2022cites this paper
• β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer

  2022cites this paper
• Pathogenicity and virulence of Hepatitis B virus

  2022cites this paper
• Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy

  2022cites this paper
• Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients

  2022cites this paper
• Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups

  2022cites this paper
• Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities

  2022cites this paper
• Immunopathogenesis of Hepatitis B Virus Infection

  2021cites this paper
• Immunotherapy Updates in Advanced Hepatocellular Carcinoma

  2021cites this paper
• Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials

  2021cites this paper
• HBV-Specific CD8+ T-Cell Tolerance in the Liver

  2021cites this paper
• Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors

  2021cites this paper
• Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression

  2021cites this paper
• Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective

  2021cites this paper
• Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study

  2021cites this paper
• Improving Therapeutic Vaccination against Hepatitis B—Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection

  2021cites this paper
• Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B

  2021cites this paper
• Novel Therapies of Hepatitis B and D

  2021cites this paper
• Risk of Hepatitis B Virus Reactivation in Patients Treated with Immunotherapy for Anti-cancer Treatment.

  2021cites this paper
• Dynamics of Immune Activation in Viral Diseases

  2020cites this paper
• Functional responses of resident human T cells in intact liver tissue.

  2020cites this paper
• Metabolic regulation of the HBV-specific T cell function.

  2020cites this paper
• PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response

  2020cites this paper
• A PEPTIDE-BASED CHECKPOINT IMMUNOMODULATOR ALLEVIATES IMMUNE DYSFUNCTION IN MURINE POLYMICROBIAL SEPSIS

  2020cites this paper
• PD-L1 is induced on hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 upregulation by the anti-HBV drug Entecavir.

  2020cites this paper
• Interleukin 15 upregulates the expression of PD-1 and TIM-3 on CD4+ and CD8+ T cells.

  2020cites this paper
• Immune Checkpoints in Viral Infections

  2020cites this paper
• Entecavir Plus Pegylated Interferon and Sequential HBV Vaccination Increases HBsAg Seroclearance: A Randomized Controlled Proof-of-Concept Study.

  2020cites this paper
• Hepatitis B Virus Reactivation Potentiated by Biologics.

  2020cites this paper
• Role of Immune Cells in Hepatitis B Infection

  2020cites this paper
• Diverse Virus and Host-Dependent Mechanisms Influence the Systemic and Intrahepatic Immune Responses in the Woodchuck Model of Hepatitis B

  2020cites this paper
• Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma

  2020cites this paper
• The Role of Diverse Liver Cells in Liver Transplantation Tolerance

  2020cites this paper
• Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice

  2019cites this paper
• Programmed cell death protein 1 promotes hepatitis B virus transmission through the regulation of ERK1/2-mediated trophoblasts differentiation

  2019cites this paper
• PD-1 Upregulation Is Associated with Exhaustion of Regulatory T Cells and Reflects Immune Activation in HIV-1-Infected Individuals

  2019cites this paper
• Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study.

  2019cites this paper
• Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection

  2019cites this paper
• A global scientific strategy to cure hepatitis B.

  2019cites this paper
• YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.

  2019cites this paper
• Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.

  2019cites this paper
• The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance

  2019cites this paper
• Current concepts on immunopathogenesis of hepatitis B virus infection.

  2018cites this paper
• Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report

  2018cites this paper
• Prostaglandin E2 facilitates Hepatitis B virus replication by impairing CTL function

  2018cites this paper
• Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

  2018cites this paper
• In vitro and in vivo effect of PD‐1/PD‐L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis

  2018cites this paper
• Discrepant Clinical Significance of CD28+CD8− and CD4+CD25high Regulatory T Cells During the Progression of Hepatitis B Virus Infection

  2018cites this paper
• PD-L1 Expression on Circulating CD34+ Hematopoietic Stem Cells Closely Correlated with T-cell Apoptosis in Chronic Hepatitis C Infected Patients

  2017cites this paper
• Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection

  2017cites this paper
• Novel therapies and potential therapeutic targets in the management of chronic hepatitis B

  2017cites this paper
• Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions

  2017cites this paper
• Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection

  2017cites this paper
• THE MECHANISMS OF IMMUNE ESCAPE BY HEPATITIS B VIRUS

  2017cites this paper
• Immune checkpoint blockade in infectious diseases

  2017cites this paper
• HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo

  2017cites this paper
• Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets

  2017cites this paper
• The tumor-draining lymph nodes are immunosuppressed in patients with hepatocellular carcinoma

  2017cites this paper
• Intrahepatic Toll-Like Receptor 3 in Subjects with Chronic HBV Infection and Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma

  2016cites this paper
• New therapeutic agents for chronic hepatitis B.

  2016cites this paper
• Molecular mechanisms of HBeAg in persistent HBV infection

  2016cites this paper
• Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

  2016cites this paper
• New therapies for chronic hepatitis B

  2016cites this paper
• Subset- and Antigen-Specific Effects of Treg on CD8+ T Cell Responses in Chronic HIV Infection

  2016cites this paper
• Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission.

  2016cites this paper
• Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy

  2016cites this paper
• Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

  2016cites this paper
• Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.

  2016cites this paper
• Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice

  2016cites this paper
• Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma

  2016cites this paper
• The CD8 T-cell response during tolerance induction in liver transplantation

  2016cites this paper
• Presentation of hepatocellular antigens

  2016cites this paper
• Modes of Antigen Presentation by Lymph Node Stromal Cells and Their Immunological Implications

  2015cites this paper
• The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.

  2015cites this paper
• T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance

  2015cites this paper
• The Role of Immune Cells in Chronic HBV Infection

  2015cites this paper
• Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells

  2015cites this paper
• Association of genetic polymorphisms in CD8+ T cell inhibitory genes and susceptibility to and progression of chronic HBV infection.

  2015cites this paper
• PD-1 Deficiency Enhances Humoral Immunity of Malaria Infection Treatment Vaccine

  2015cites this paper
• Immune outcomes in the liver: Is CD8 T cell fate determined by the environment?

  2015cites this paper
• Functional and phenotypic characterization of CD4 T cells involved in immunopathogenesis of hepatitis B virus infection

  2015cites this paper
• Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters

  2015cites this paper
• PD-1 deficiency Enhances Humoral Immunity of Malaria 1 infection-treated vaccine

  2015cites this paper
• Balancing viral replication in spleen and liver determines the outcome of systemic virus infection

  2015cites this paper
• Interferon alpha induces generation of semi-mature dendritic cells with high pro-inflammatory and cytotoxic potential.

  2015cites this paper
• Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV

  2015cites this paper
• microRNA-4717 differentially interacts with its polymorphic target in the PD1 3′ untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases

  2015cites this paper